Skip to main content

On This Page

← AI Financial News

Applied Digital Corporation – 2026-01-09 - increase Confidence 8/10

2 min read $APLD
Share

These articles are AI-generated summaries. Please check the original sources for full details.

APLDApplied Digital Corporation
$27.86+8.51 (+43.98%)
$38$29$19Sep 15Oct 29Dec 12
52W High: $37.7652W Low: $19.35Volume: 24.67M
NasdaqGS
Prediction (1/23/2026):High: $40.2Low: $3.31Ref Price: $37.68
This chart shows historical data as of December 12, 2025. Not updated in real-time.

APLD – increase in Days/Weeks

Applied Digital reported a 250% year-over-year revenue surge to $126.6M in Q2 2026, far exceeding expectations. This beat was fueled by major new hyperscaler leasing deals, including a 200MW agreement, and amplified by a massive $2.9B in fresh capital from debt and credit facilities.

Why This Matters

Despite deeply negative free cash flow (-$797M TTM) and a sky-high debt/equity ratio of 125.9, the company’s financial trajectory has fundamentally shifted due to secured, high-margin demand from AI hyperscalers—validating its infrastructure build-out strategy. The market is currently pricing in growth rather than profitability, and with Wall Street’s average price target at $42.90, the recent earnings catalyst has created strong momentum likely to persist over the next few weeks.

Key Insights

  • Revenue Growth: Q2 2026 revenue of $126.6M, up 250% YoY, signaling strong demand for AI/data center capacity.
  • News Impact: $2.35B private note offering and $562.5M draw from Macquarie provide runway for expansion, reducing near-term liquidity risk.
  • Risk/Offset: Debt burden remains extreme (Debt/Equity >125), but growth in NOI and investment-grade tenant contracts de-risk near-term default.

Practical Implications

  • Bull Case: Continued momentum from earnings beat and analyst upgrades could drive the stock toward its 52-week high of $40.20 within the next two weeks.
  • Bear Case: If broader tech or AI stocks sell off due to rate concerns, APLD’s high leverage could amplify downside, though catalysts are currently outweighing risks.
  • Confidence: 8/10 – Strong earnings, institutional capital, and hyperscaler validation support near-term upside.

Prediction: increase

Reference:

Continue reading

Next article

CG Oncology – 2026-01-09 - Increase Confidence 8/10

Related Content